Huntington's Disease is a hereditary and degenerative condition of the central nervous system (CNS) which carries a 50% risk of being inherited by the children of an affected parent. This devastating disease - for which there is no known cure - affects a wide range of brain activities and symptoms gradually become apparent in middle age. Changes in personality or mood may be the earliest signs of the disease, followed by problems with memory and involuntary movements (chorea).
Xenazine™ is proven to be effective in the treatment of the chorea associated with Huntington's Disease. It is also effective in a range of other movement disorders, including hemiballismus, senile chorea, dystonia and Tourette's syndrome. It can also be used to control iatrogenic movement disorders, such as Tardive Dyskinesia, caused by the prolonged use of antipsychotic medication.
By depleting the stores of neurotransmitters, including dopamine, serotonin and noradrenaline, within nerve cells in the brain, Xenazine™ alters the transmission of electric signals from the brain that control movement.
Xenazine™ is generally well tolerated and patients have been maintained on treatment for many years. Its safety profile is supported by more than 30 years of clinical experience.
Xenazine™ is currently licensed in Australia, Canada, Denmark, France, Germany, Israel, Italy, Netherlands, New Zealand, Portugal and the UK, with license applications pending in several other European territories and the USA.